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For the second time in as many years
the Treatment Action Campaign (TAC)
has speeded up the government's
provision of AIDS drugs, this time by
carefully preparing and then merely
threatening, court action.
Their confidence buoyed by three
court victories that ensured government
provided nevirapine to prevent mother-
to-child HIV transmission 2 years ago,
the TAC has again got ARV drugs
flowing months quicker than the
government claimed possible.
National health chiefs told parliament
in late February that the ARV medicines
on tender were expected to be issued in
the last week of May, with delivery to
the accredited treatment sites 2 - 3
weeks later. 
Provinces depend on national
government for the procurement and
supply of medicines. In a 'letter of
demand' served on the Minister of
Health and her nine provincial
counterparts, the TAC argued there was
'no rational, reasonable or lawful basis'
for the State's failure to urgently
procure ARV drugs on an interim basis,
pending the finalisation of the tender
process.
It also highlighted precisely which
laws the government could use to do so.
The TAC said that with an estimated
600 people dying of AIDS daily, failure
to provide an interim solution would
result in 'irreparable medical harm to
and/or premature deaths of people
living with HIV/AIDS in situations
where this is both predictable and
avoidable'.
Provinces that had not struck up
private funding partnerships were
hamstrung by a law forcing them to use
current conditional grant allocations to
buy only medicines procured in terms
of the national tender process.
TAC lawyers (specifically the AIDS
Law Project at Wits University) gave the
government until end of March to speed
up the drugs flow to the more than 40
sites across the country capable of safely
and effectively treating qualifying
patients.
A MinMEC (Health Minister and her
provincial counterparts) meeting in late
March then promptly decided to use an
(alternative) national comparative price
quotation system to buy ARV drugs
until the tender procedure was
finalised.
This enabled provinces to use their
conditional grants to buy the drugs
from central government far sooner
than the tender process would have
otherwise allowed.
Dr Manto Tshabalala-Msimang
confidently asserted in early March that
the national tender mechanism would
'have to' be followed. Her spokesman,
Sibani Mngadi, told the SAMJ, 'We now
have 27 HIV and AIDS service sites
accredited and this will enable
provinces to properly quantify their
drug orders and let us get decent
estimates of what's required initially'.
Speaking on 1 April, he said the drug
supplier quotes 'should be in within 3
or 4 days and we can then identify the
cheapest, safest supplier. After that we'll
be able to tell you exactly when the
drugs should reach the central
provincial depots'.
There are an estimated 110 sites that
Health Department inspectors are
visiting to ensure capacity and quality
control, of which they have so far
accredited 27.
The aim is to have a central ARV drug
depot in every one of the country's 53
health districts.
Mngadi said a 5-year target was to
have accessible ARV services at
municipal level throughout the country.
Mrs Felicia Serenata, National Project
Manager for HIV/AIDS, told the SAMJ
that the 'three quotes system' was also
being used to fast-track health care
worker training. This was because a
'technical dispute' around the proper
advertising of the training tender had
caused delays.
The dispute was only due to be
adjudicated in mid-April, so her staff
had provisionally gone ahead and
secured quotes.
'We're primarily using the
Foundation for Professional
Development, but there's also your
ATTICs and other service providers
doing training,' she said.
The TAC said that with an
estimated 600 people dying of
AIDS daily, failure to provide
an interim solution would
result in 'irreparable medical
harm to and/or premature
deaths of people living with
HIV/AIDS in situations where
this is both predictable and
avoidable'.
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A pregnant protestor during the TAC protest
march in Cape Town on 14 February last year.
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She estimated that 700 health-care
workers would be trained country-wide
by the end of April or early in May,
'depending on when the training tender
kicks in'.
Mrs Rose Mdlalose, Director for
Human  Resource Development in the
national health department, said the
training manual and guidelines had
been approved.
Her department would support the
five provinces that had the most limited
resources, starting with Mpumalanga.
She listed the others as North West, the
Eastern Cape, Northern Cape and
Limpopo.
Serenata said electronic versions of
the treatment guidelines were being e-
mailed to those provinces ready to use
them because 'hard copies' were still
being printed.
A national department of health
media update at the end of March said
the ARV site accreditation process was
'exposing major gaps' in the national
health system.
Flaws included a poor patient
information system, provincial health
information systems that did not talk to
one another, the lack of a
comprehensive laboratory service
network at point of service, poor
recruitment and retention of medical,
nursing and pharmacy staff and the lack
of a baseline survey 'to establish our
starting point'.
The department said it saw the job of
accredited facilities as HIV testing, CD4
cell and viral load counts, providing
nutritional and micronutrient
supplements and providing traditional
medicines and improving step-down
referral facilities.
Treatment literacy was a priority to
ensure compliance for those patients
'who qualify for and prefer
antiretroviral therapy'.
Cabinet adopted a comprehensive
HIV/AIDS treatment plan on 19
November last year that included a
target to roll out antiretroviral therapy
to 53 000 people nation-wide by 31
March this year. Instead, some 2 500
people were estimated to be on ARVs
by that date, most of them in the
Western Cape and relying on private,
provincially facilitated, drug funding.
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Is combination therapy more beneficial after AMI?
In patients referred for post-infarction percutaneous coronary intervention (PCI), pharmacological therapy is usually
applied in the interval between the onset of the acute myocardial infarction (AMI) admission to the treatment facility and
performance of the treatment. The optimal pharmacological therapy for this period is not known. A trial was recently
conducted to assess whether early administration of reteplase (a fibrinolytic agent) and abciximab (an anti-platelet agent)
produces better results with PCI. The trial involved 253 patients who were randomised either to the combination therapy or
to abciximab alone prior to PCI. The researchers concluded that the combination therapy does not lead to a reduction of
infarct size compared with abciximab alone, and clinical outcome was not improved. The latter finding, they say, should be
interpreted with caution, and deserves confirmation from the larger ongoing FINESSE trial. 
(JAMA 2004; 291: 947-954)
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